Oncotarget is an open access peer-reviewed medical journal that is published weekly. It covers research dealing with all aspects of oncology. Established in 2010, the journal is produced by Impact Journals. Andrei V. Gudkov and Mikhail Blagosklonny are the editors-in-chief. The publication is indexed and abstracted in BIOSIS Previews, Index Medicus/MEDLINE/PubMed, Scopus and the Science Citation Index Expanded. Journal Citation Reports said Oncotarget had 5.008 2015 impact factor. Without journal self cites the impact factor is 3.757. It is a highly respected publication. See: https://pubpeer.com/journals/Oncotarget
The publication is considered a multidisciplinary traditional journal. It is available in an online or a printed version. People can make a special demand and have an issue of the publication printed. Oncotarget has several goals. They include:
1. Disseminating scientific results as quickly and as widely as possible.
2. Allowing for insightful review to maximize the research’s impact.
3. Providing an avenue for the rapid sharing of exceptional discoveries.
4. Remove borders between the specialties in the field.
5. Linking biomedical science’s different fields.
6. Fostering basic and clinical science applications to fight disease.
Under the guidance and leadership of today’s most prominent scientists, Oncotarget assists all researchers by allowing them to contribute to the progress made by science. The publication’s ultimate goal is life without disease. The publication has been so well received that it has begun to include sections dealing with topics beyond oncology. However, the main focus of Oncotarget remains looking at all cancers’ pathological basis, identifying targets for therapy and treatment protocols that can be used to improve cancer patients’ management.
Oncotarget focuses on how management programs along with new therapeutic protocols and agents impact patient perspectives on adherence, satisfaction and quality of life.
The international journal explores evidence that led to the many exciting new therapies as well as established ones that improve outcomes. It also seeks to define how they should be used relative to uptake and acceptance by both patients and health care professionals. Recent studies published by Oncotarget focused on the impact of e-cigarettes and gum disease and MET amplification and how it can be a potential therapeutic option for patients suffering with gastric cancer.
With just a few keystrokes researchers, health care professionals and patients can get reliable information on the recent breakthroughs and promising treatments and therapies being considered for use in treating a wide variety of cancers. The publication is a useful resource.
Learn about Oncotarget on DovePress.com